Very interesting to see Oxford Nanopore exploring an opportunity to bring nanopore sequencing as a consumer-facing diagnostic for infectious diseases. This could provide rapid-response to outbreaks like COVID, but in a way that’s low-cost and with an extremely fast turnaround time.
Oxford is headquartered in the UK and is traded primarily on the London Stock Exchange, though international investors can buy ADRs through the ticker “ONTTF.” I think the have an innovative leadership team and are responding adeptly to the medical world’s growing need for low-cost, fast-response, consumer-friendly diagnostics.
